Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Determination of apolipoprotein(a) (apo(a)) phenotype and lipoprotein(a) (Lp(a)) concentration in plasma revealed that in many instances, involving individuals with various apo(a) phenotypes, there was no difference in plasma Lp(a) concentration between an FH heterozygote and an unaffected sibling with the same apo(a) phenotype.
|
1830890 |
1991 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diverse effect of ethnicity on plasma lipoprotein[a] levels in heterozygote patients with familial hypercholesterolemia.
|
1836489 |
1991 |
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The substantial acute reduction of lipoprotein (a) (means: 65%, heterozygous FH; 68%, homozygous FH) has not been reported with other therapies.
|
1414897 |
1992 |
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection of the Pro664-Leu mutation in the low-density lipoprotein receptor and its relation to lipoprotein(a) levels in patients with familial hypercholesterolemia of Dutch ancestry from The Netherlands and Canada.
|
1493640 |
1992 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An investigation of the influence of selected factors on the clinical expression of the FH Afrikaner-1 mutation in this family indicated that it was especially the elevated apolipoprotein (a) levels, in addition to low levels of high density lipoprotein cholesterol and raised triglyceride and apolipoprotein B levels, that were associated with a greater risk of developing CHD.
|
8370148 |
1993 |
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration.
|
8500516 |
1993 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The short-term effects of low-density lipoprotein (LDL) apheresis using a dextran sulfate-cellulose (DSC) column equipped with a plasma separator using a polysulfone (PS) membrane filter on the serum total cholesterol, lipoprotein(a) (Lp(a)), C4b binding protein (C4bp), protein C and protein S and complement components levels were examined in a patient with familial hypercholesterolemia (heterozygote, type IIa).
|
9222877 |
1994 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of lipoprotein (a) in children with familial hypercholesterolemia.
|
8197753 |
1994 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemia.
|
7607414 |
1995 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The possible influence of apo E polymorphism on components of variation in plasma LDL-C, triglycerides, high-density lipoprotein cholesterol (HDL-C), and lipoprotein(a) (Lp(a)) levels was investigated in 235 members of 14 families with FH.
|
8722744 |
1996 |
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein (a) [apo(a)] phenotype was determined in 112 of FH and non-FH subjects.
|
8548413 |
1996 |
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study's aim was to determine whether biochemical risk factors such as lipoprotein(a), fibrinogen, homocysteine, and insulin, as well as low-density lipoprotein (LDL) particle size, were predictive of carotid intimamedia thickness (IMT), an early marker of atherosclerosis, in subjects with familial hypercholesterolemia (FH).
|
10235090 |
1999 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated lipoprotein(a) levels contribute to the occurrence and severity of early-onset coronary disease and add to the already enhanced risk in patients with familial hypercholesterolaemia.
|
12889664 |
2003 |
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phenotypic diversity of familial hypercholesterolemia (FH) and lipoprotein(a) hyperlipidemia (Lp(a)-HLP), as defined risks for coronary artery disease with genetic background, and their frequent co-incidence with additional cardiovascular risk factors require a critical revisiting of the current diagnostic and screening criteria as well as therapeutic recommendations established for FH or isolated Lp(a)-HLP, since there is no clear guidance for patient stratification and disease management for combined cases.
|
20129380 |
2009 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Total cholesterol and lipoprotein (a) were increased in FH children compared to controls (282.3+/-8.8 mg/dl vs. 163.8+/-4.6 mg/dl and 11.0[4.6, 30.7]mg/dl vs. 5.24[2.63, 11.0]mg/dl median [IQR] respectively; p<0.001 for both).
|
19004443 |
2009 |
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase 2 and 3 clinical trials in patients with moderate and severe hypercholesterolemia (including FH) show that this approach is safe and highly efficacious to lower LDL-C and lipoprotein(a).
|
25248569 |
2014 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.
|
24632281 |
2014 |
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] increases CAD in FH, although the independence of this association relative to other CAD risk factors remains unclear.
|
26340131 |
2015 |
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the relationship between LDLR genotype and the plasma levels of PCSK9, LDL-C, and lipoprotein (a) (Lp(a)) in a large cohort of genetically defined FH heterozygotes (HeFH).
|
26371983 |
2015 |
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The metabolic defects in FH extend beyond LDL, and may affect triacylglycerol-rich and high-density lipoproteins, lipoprotein(a) and oxidative stress.
|
25881720 |
2015 |
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, when adjusting LDL cholesterol for lipoprotein(a) cholesterol content the corresponding values were 24 mg/dL for individuals unlikely to have familial hypercholesterolaemia, 22 mg/dL for those with possible familial hypercholesterolaemia, and 21 mg/dL for those with probable or definite familial hypercholesterolaemia (ptrend=0·46).
|
27185354 |
2016 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
|
27594539 |
2016 |
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
|
26632531 |
2016 |
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
to analyze the relationship between lipid disturbance, including lipoprotein(a) (Lp(a)) levels, and development of ischemic heart disease (IHD) in patients with familial hypercholesterolemia (FH).
|
29096862 |
2017 |
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to investigate the associations of lipoprotein (a) [Lp(a)] with the FH phenotype, genotype and roles of Lp(a) in determining CAD risk among patients with and without FH.
|
28351002 |
2017 |